The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC)
Clinical Breast Cancer · 2024
DOI: 10.1016/j.clbc.2024.03.001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Breast Cancer, 2024. Verfasst von Elena Michaels und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, The University of Chicago Medicine, Chicago, IL. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Immunotherapy. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 66 Literaturangaben.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype, generally associated with a high risk of recurrence and poor prognosis. Our understanding of the heterogeneity of TNBC has increased over the past decade, and with it a recognition that some TNBCs are immunogenically active. This finding has led to the investigation of immunotherapy-based approaches for treatment of both early and advanced-stage TNBC. In this review, we provide an overview of the biologic rationale for immunotherapy use in TNBC, and review data from seminal trials which have culminated in the approval of immunotherapy for both early and advanced TNBC. Identification of predictive biomarkers to aid in treatment selection, development of novel treatment combinations to combat resistance, and refinement of therapeutic targets enables continued improvement in outcomes with immunotherapy for TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, The University of Chicago Medicine, Chicago, IL.
- Department of Medicine, The University of Chicago Medicine, Chicago, IL; Department of Medicine, The University of Chicago Comprehensive Cancer Center, Chicago, IL.
- Department of Medicine, The University of Chicago Medicine, Chicago, IL; Department of Medicine, The University of Chicago Comprehensive Cancer Center, Chicago, IL. Electronic address: rnanda@medicine.bsd.uchicago.edu.
Zitieren
APA
Michaels, E., Chen, N., & Nanda, R. (2024). The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC). Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.03.001
Vancouver
Michaels E, Chen N, Nanda R. The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC). Clinical Breast Cancer. 2024. doi:10.1016/j.clbc.2024.03.001
BibTeX
@article{Michaels2024,
author = {Michaels, Elena and Chen, Nan and Nanda, Rita},
title = {The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC)},
journal = {Clinical Breast Cancer},
year = {2024},
doi = {10.1016/j.clbc.2024.03.001}
}
EUVIMED